Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma ; volume:10 ; number:1 ; day:4 ; month:10 ; year:2010 ; pages:1-10 ; date:12.2010
BMC cancer ; 10, Heft 1 (4.10.2010), 1-10, 12.2010
- Urheber
- Beteiligte Personen und Organisationen
- DOI
-
10.1186/1471-2407-10-524
- URN
-
urn:nbn:de:1111-2016030357862
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
Ähnliche Objekte (12)
Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma
Pathogenesis of human hepatocellular carcinoma
Pemigatinib : erste zielgerichtete Zweitlinientherapie beim Cholangiokarzinom mit FGFR2-Fusion/Rearrangement
Molecular diagnostics of hepatobiliary and pancreatic neoplasias
Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications
Opposite effects of tissue inhibitor of metalloproteinases-1 (TIMP-1) over-expression and knockdown on colorectal liver metastases
Functional analysis and targeted inhibition of the enhancer of zeste homolog 2 (EZH2)-protein in human cancer cells
Expression of apoptosis repressor with caspase recruitment domain (ARC) in familial adenomatous polyposis (FAP) adenomas and its correlation with DNA mismatch repair proteins, p53, Bcl-2, COX-2 and beta-catenin
Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types
Analysis of the correlation between Zeste enhancer homolog 2 (EZH2) mRNA expression and the prognosis of mesothelioma patients and immune infiltration
Targeting enhancer of zeste homolog 2 protects against acute kidney injury
Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study
Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma
Pathogenesis of human hepatocellular carcinoma
Pemigatinib : erste zielgerichtete Zweitlinientherapie beim Cholangiokarzinom mit FGFR2-Fusion/Rearrangement
Molecular diagnostics of hepatobiliary and pancreatic neoplasias
Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications
Opposite effects of tissue inhibitor of metalloproteinases-1 (TIMP-1) over-expression and knockdown on colorectal liver metastases
Functional analysis and targeted inhibition of the enhancer of zeste homolog 2 (EZH2)-protein in human cancer cells
Expression of apoptosis repressor with caspase recruitment domain (ARC) in familial adenomatous polyposis (FAP) adenomas and its correlation with DNA mismatch repair proteins, p53, Bcl-2, COX-2 and beta-catenin
Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types
Analysis of the correlation between Zeste enhancer homolog 2 (EZH2) mRNA expression and the prognosis of mesothelioma patients and immune infiltration
Targeting enhancer of zeste homolog 2 protects against acute kidney injury
Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study
Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma
Pathogenesis of human hepatocellular carcinoma
Pemigatinib : erste zielgerichtete Zweitlinientherapie beim Cholangiokarzinom mit FGFR2-Fusion/Rearrangement
Molecular diagnostics of hepatobiliary and pancreatic neoplasias
Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications
Opposite effects of tissue inhibitor of metalloproteinases-1 (TIMP-1) over-expression and knockdown on colorectal liver metastases
Functional analysis and targeted inhibition of the enhancer of zeste homolog 2 (EZH2)-protein in human cancer cells
Expression of apoptosis repressor with caspase recruitment domain (ARC) in familial adenomatous polyposis (FAP) adenomas and its correlation with DNA mismatch repair proteins, p53, Bcl-2, COX-2 and beta-catenin
Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types
Analysis of the correlation between Zeste enhancer homolog 2 (EZH2) mRNA expression and the prognosis of mesothelioma patients and immune infiltration
Targeting enhancer of zeste homolog 2 protects against acute kidney injury